Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
Key claim: A clinical trial is evaluating the effectiveness, safety, and tolerability of fedratinib in patients with MDS/MPN overlap syndromes and chronic neutrophilic leukemia.
Abstract
The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
Why this matters
MDS/MPN overlap syndromes and CNL are rare, biologically heterogeneous BCR::ABL1-negative myeloid neoplasms with limited prospective therapeutic evidence and management largely extrapolated from MDS or classic MPN paradigms. A dedicated fedratinib trial extends selective JAK2 inhibition — already established in myelofibrosis — into these underexplored subtypes, and importantly tests whether a CSF3R/JAK-STAT-driven disease (CNL) and dysplastic-proliferative overlap entities respond similarly to a shared targeted strategy.